Freeform Search

1007+383

Database:	US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index				
Term:	IBM Technical Disclosure Bulletins 13 and RNAseH				
Display: Generate:	Documents in Display Format: - O Hit List O Hit Count O Side by Side O	Starting with Number 1			
Search Clear Interrupt					
Search History					

DATE: Thursday, January 06, 2005 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=U	SPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
<u>L7</u>	13 and RNAseH	4	L7
L6	14 and reverse transcriptase\$1	0	<u>L6</u>
<u>L5</u>	l3 and (reverse transcriptase\$1 near5 (lack\$1 or devoid\$3) near5 RNaseH)	0	L5
<u>L4</u>	L3 and (reverse transcriptase near5 lack\$1 near5 RNaseH)	0	L4
<u>L3</u>	(primer\$1 or oligonucleotide\$1) same (brideg\$3 sequence\$1 or spac\$3 sequence\$1)	239	L3
L2	L1 and (reverse transcriptase\$1 near5 lack\$1 near5 RNAseH)	1	L2
<u>L1</u>	(primer\$1 or oligonucleotide\$1)same (brideg\$3 or spac\$3)	5030	<u>L1</u>

END OF SEARCH HISTORY

```
> s (primer# or oligonucleotide#) (P) (brideg### sequence# or spac### sequence#)
           291 (PRIMER# OR OLIGONUCLEOTIDE#) (P) (BRIDEG### SEQUENCE# OR SPAC##
L1
               # SEQUENCE#)
=> s l1 and reverse transcriptase#(10a)lack#(10a)RNAseH
             0 L1 AND REVERSE TRANSCRIPTASE#(10A) LACK#(10A) RNASEH
L2
    s l1 and (reverse transcriptase#(10a)lack#(10a)RNAseH)
             0 L1 AND (REVERSE TRANSCRIPTASE#(10A) LACK#(10A) RNASEH)
L3
=> s ll and reverse transcriptase#
             8 L1 AND REVERSE TRANSCRIPTASE#
L4
=> s 14 and RNAseH
L5
             1 L4 AND RNASEH
=> d l5 bib ab kwic
L5
     ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
     2002:946303 CAPLUS
\mathbf{N}\mathbf{A}
DN
     138:1057
     Nucleic acid amplification utilizing intermediate duplexes
TI
     Haydock, Paul V.; U'Ren, Jack
IN
     Saigene Corporation, USA
PA
     PCT Int. Appl., 69 pp.
SO
     CODEN: PIXXD2
     Patent
DT
     English
LA
FAN.CNT 1
     PATENT NO.
                         KIND
                                DATE
                                           APPLICATION NO.
                                                                    DATE
                         ----
ΡI
     WO 2002098895
                          A1
                                20021212
                                            WO 2002-US18229
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                20030313
     US 2003050444
                          A1
                                            US 2002-77383
                                                                    20020215
                          A1
                                20040407
     EP 1404697
                                            EP 2002-737437
                                                                    20020607
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                20010607
PRAI US 2001-296812P
                          Р
     US 2002-77383
                          Α
                                20020215
     WO 2002-US18229
                          W
                                20020607
OS
     MARPAT 138:1057
     This invention provides for a novel amplification procedure for nucleic
AB
     acid. The method uses a wild type or mutant RNA polymerase designed to
     transcribe both deoxyribonucleotides and ribonucleotides. The invention
     provides for oligonucleotide primers that comprise in
     the following order from 5' to 3': a phage-encoded RNA polymerase
     recognition sequence, a spacer sequence comprising a
     sequence of from 12 to 20 nucleotides that consists of one nucleotide or
     two different nucleotide types, and a target complimentary sequence which
     can bind a segment of a target nucleic acid. The target nucleic acid can
    be ssDNA or comprised of RNA. The invention further provides a kit for
     amplifying a target nucleic acid, containing a wild type or a mutant phage RNA
    polymerase competent to incorporate dNTP and rNTP simultaneously into a
     template nucleic acid.
RE.CNT 1
              THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
```

ALL CITATIONS AVAILABLE IN THE RE FORMAT This invention provides for a novel amplification procedure for nucleic AB acid. The method uses a wild type or mutant RNA polymerase designed to transcribe both deoxyribonucleotides and ribonucleotides. The invention provides for oligonucleotide primers that comprise in the following order from 5' to 3': a phage-encoded RNA polymerase recognition sequence, a spacer sequence comprising a sequence of from 12 to 20 nucleotides that consists of one nucleotide or two different nucleotide types, and a target complimentary sequence which can bind a segment of a target nucleic acid. The target nucleic acid can be ssDNA or comprised of RNA. The invention further provides a kit for amplifying a target nucleic acid, containing a wild type or a mutant phage RNA polymerase competent to incorporate dNTP and rNTP simultaneously into a template nucleic acid. nucleic acid amplification phage RNA polymerase kit SToligonucleotide primer; intermediate duplex amplification spacer sequence dNTP rNTP 9068-38-6, Reverse transcriptase IT RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNaseH-; nucleic acid amplification utilizing intermediate duplexes)

```
=> dup rem 14
PROCESSING COMPLETED FOR L4
              3 DUP REM L4 (5 DUPLICATES REMOVED)
Lб
=> d 16 1-3 bib ab kwic
     ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
L6
AN
     2002:946303 CAPLUS
DN
     138:1057
     Nucleic acid amplification utilizing intermediate duplexes
TI
     Haydock, Paul V.; U'Ren, Jack
IN
     Saigene Corporation, USA
PA
     PCT Int. Appl., 69 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
     PATENT NO.
                         KIND
                                DATE
                                             APPLICATION NO.
PI
     WO 2002098895
                                             WO 2002-US18229
                          A1
                                 20021212
```

```
DATE
                                                                     20020607
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2003050444
                          A1
                                20030313
                                            US 2002-77383
                                                                    20020215
     EP 1404697
                          A1
                                20040407
                                            EP 2002-737437
                                                                    20020607
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI US 2001-296812P
                          Ρ
                                20010607
     US 2002-77383
                          Α
                                20020215
     WO 2002-US18229
                          W
                                20020607
OS
     MARPAT 138:1057
```

AB This invention provides for a novel amplification procedure for nucleic acid. The method uses a wild type or mutant RNA polymerase designed to transcribe both deoxyribonucleotides and ribonucleotides. The invention

provides for oligonucleotide primers that comprise in the following order from 5' to 3': a phage-encoded RNA polymerase recognition sequence, a spacer sequence comprising a sequence of from 12 to 20 nucleotides that consists of one nucleotide or two different nucleotide types, and a target complimentary sequence which can bind a segment of a target nucleic acid. The target nucleic acid can be ssDNA or comprised of RNA. The invention further provides a kit for amplifying a target nucleic acid, containing a wild type or a mutant phage RNA polymerase competent to incorporate dNTP and rNTP simultaneously into a template nucleic acid.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- AB This invention provides for a novel amplification procedure for nucleic acid. The method uses a wild type or mutant RNA polymerase designed to transcribe both deoxyribonucleotides and ribonucleotides. The invention provides for oligonucleotide primers that comprise in the following order from 5' to 3': a phage-encoded RNA polymerase recognition sequence, a spacer sequence comprising a sequence of from 12 to 20 nucleotides that consists of one nucleotide or two different nucleotide types, and a target complimentary sequence which can bind a segment of a target nucleic acid. The target nucleic acid can be ssDNA or comprised of RNA. The invention further provides a kit for amplifying a target nucleic acid, containing a wild type or a mutant phage RNA polymerase competent to incorporate dNTP and rNTP simultaneously into a template nucleic acid.
- nucleic acid amplification phage RNA polymerase kit oligonucleotide primer; intermediate duplex amplification spacer sequence dNTP rNTP
- PAGE 138-6, Reverse transcriptase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RNaseH-; nucleic acid amplification utilizing intermediate duplexes)
- L6 ANSWER 2 OF 3 MEDLINE on STN DUPLICATE 1
- AN 94118405 MEDLINE
- DN PubMed ID: 7507181
- TI A specific orientation of RNA secondary structures is required for initiation of reverse transcription.
- AU Aiyar A; Ge Z; Leis J
- CS Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106.
- NC CA38046 (NCI) P30 CA 43703 (NCI)
- SO Journal of virology, (1994 Feb) 68 (2) 611-8. Journal code: 0113724. ISSN: 0022-538X.
- CY United States
- DT Journal; Article; (JOURNAL ARTICLE)
- LA English
- FS Priority Journals; AIDS
- EM 199402
- ED Entered STN: 19940312 Last Updated on STN: 19970203 Entered Medline: 19940218
- The 5' end of avian retrovirus RNA near the primer-binding site (PBS) forms two secondary structures, the U5-inverted repeat (U5-IR) and the U5-leader stems, and contains a 7-nucleotide sequence that anneals to the T psi C loop of the tRNA(Trp) primer. Mutations that disrupt any of these base pair interactions cause defects in initiation of reverse transcription both in vivo and in vitro (D. Cobrinik, A. Aiyar, Z. Ge, M. Katzman, H. Huang, and J. Leis, J. Virol. 65:3864-3872, 1991; A. Aiyar, D. Cobrinik, Z. Ge, H.-J. Kung, and J. Leis, J. Virol. 66:2464-2472, 1992). We have now examined the effect of perturbing the non-base-paired intervening "spacer" sequences between these secondary-structure elements. Small deletions or insertions in these intervening sequences decreased initiation of reverse

transcription in vitro. In contrast, base substitutions, which maintain the spacing distances between the structures, had no detectable effect. Additionally, a small deletion at the 3' end of the PBS caused a significant decrease in initiation of reverse transcription whereas substitution mutations again had no effect. Together, these results indicate that reverse transcriptase forms a complex in which the different structural elements are maintained in a specific orientation that is required for efficient initiation of reverse transcription. Specific sequence recognition of the duplex structures by reverse transcriptase is also required since mosaic RNAs that combine the human immunodeficiency virus type 1 PBS with avian sequences is not efficiently utilized for reverse transcription even though the primer used can anneal to the substituted PBS. The 5' end of avian retrovirus RNA near the primer-binding site AB (PBS) forms two secondary structures, the U5-inverted repeat (U5-IR) and the U5-leader stems, and contains a 7-nucleotide sequence that anneals to the T psi C loop of the tRNA(Trp) primer. Mutations that disrupt any of these base pair interactions cause defects in initiation of reverse transcription both in vivo and. . . H.-J. Kung, and J. Leis, J. Virol. 66:2464-2472, 1992). We have now examined the effect of perturbing the non-base-paired intervening "spacer" sequences between these secondary-structure elements. deletions or insertions in these intervening sequences decreased initiation of reverse transcription in vitro. In. . . a significant decrease in initiation of reverse transcription whereas substitution mutations again had no effect. Together, these results indicate that reverse transcriptase forms a complex in which the different structural elements are maintained in a specific orientation that is required for efficient initiation of reverse transcription. Specific sequence recognition of the duplex structures by reverse transcriptase is also required since mosaic RNAs that combine the human immunodeficiency virus type 1 PBS with avian sequences is not efficiently utilized for reverse transcription even though the primer used can anneal to the substituted PBS.

- L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2
- AN 1991:36720 CAPLUS
- DN 114:36720
- TI Sequence, organization and transcription of the ribosomal RNA operon and the downstream tRNA and protein genes in the archaebacterium Thermofilum pendens
- AU Kjems, Joergen; Leffers, Henrik; Olesen, Tina; Holz, Ingelore; Garrett, Roger A.
- CS Kem. Inst., Aarhus Univ., Aarhus, 8000, Den.
- SO Systematic and Applied Microbiology (1990), 13(2), 117-27 CODEN: SAMIDF; ISSN: 0723-2020
- DT Journal
- LA English
- The single rRNA (rRNA) operon from the extremely thermophilic AΒ archaebacterium T. pendens was sequenced together with the immediate downstream tRNA genes and open reading frames on both DNA strands. The genes for 16S and 23S RNA were separated by a short spacer sequence and were not followed by a 5S RNA gene. Sites of initiation and termination of the rRNA transcript, and its processing sites, were localized by S1 or mung bean nuclease mapping and by primer-directed reverse transcriptase anal. Initiation occurred primarily 187 nucleotides upstream from the 16S RNA gene, after an archaebacterial promoter and this was confirmed by a guanyltransferase capping experiment The transcript terminated inefficiently before a polypyrimidine sequence 45 nucleotides downstream from the 23S RNA gene. The 16S RNA leader sequence, the spacer region and the sequence downstream from the 23S RNA can generate extensive secondary structure, including the processing stems for the 2 rRNAs. Moreover, much of this structure is supported phylogenetically by coordinated base changes. It

is proposed that some of these double helical structures are involved in transcriptional regulation. The 16S and 23S RNA sequences were aligned with those of other organisms. Secondary structures were generated from the alignments which are characteristic of the extreme thermophiles. Moreover, phylogenetic trees were derived which placed T. pendens close to Thermoproteus tenax. The downstream tRNA genes and open reading frames each exhibited an archaebacterial promoter-like motif and a putative primary initiation site. Incomplete termination also occurred at polypyrimidine sequences. A 919-bp sequence between the 2 tRNA genes, which are located on opposing DNA strands, was rich in polypyrimidine sequences on both strands. Transcript mapping suggested that this constitutes a major termination region.

The single rRNA (rRNA) operon from the extremely thermophilic archaebacterium T. pendens was sequenced together with the immediate downstream tRNA genes and open reading frames on both DNA strands. The genes for 16S and 23S RNA were separated by a short spacer sequence and were not followed by a 5S RNA gene. Sites of initiation and termination of the rRNA transcript, and its processing sites, were localized by S1 or mung bean nuclease mapping and by primer-directed reverse transcriptase anal.

Initiation occurred primarily 187 nucleotides upstream from the 16S RNA gene, after an archaebacterial promoter and this was confirmed by a guanyltransferase capping experiment The transcript terminated inefficiently before a polypyrimidine sequence 45 nucleotides downstream from the 23S RNA gene. The 16S RNA leader sequence, the spacer region and the sequence downstream from the 23S RNA can generate extensive secondary structure, including the processing stems for the 2 rRNAs. Moreover, much of this structure is supported phylogenetically by coordinated base changes. It is proposed that some of these double helical structures are involved in transcriptional regulation. The 16S and 23S RNA sequences were aligned with those of other organisms. Secondary structures were generated from the alignments which are characteristic of the extreme thermophiles. Moreover, phylogenetic trees were derived which placed T. pendens close to Thermoproteus tenax. The downstream tRNA genes and open reading frames each exhibited an archaebacterial promoter-like motif and a putative primary initiation site. Incomplete termination also occurred at polypyrimidine sequences. A 919-bp sequence between the 2 tRNA genes, which are located on opposing DNA strands, was rich in polypyrimidine sequences on both strands. Transcript mapping suggested that this constitutes a major termination region.

=>

AB